NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment
Key Insights
NMD Pharma (search) presented preclinical data showing that skeletal muscle targeted ClC-1 (search) ion channel inhibitor improves skeletal muscle function and respiratory function in a rat model of MuSK myasthenia gravis (search).
The company's lead candidate NMD670, a first-in-class ClC-1 (search) inhibitor, is currently being evaluated in a Phase 2b clinical trial for generalized myasthenia gravis (search) following positive Phase 2a proof-of-mechanism study results.
The Phase 2b SYNAPSE-MG study initiated in June 2024 is a dose range-finding, double-blinded, placebo-controlled trial evaluating NMD670 over 21 days in patients with anti-AChR or anti-MuSK antibody positive generalized myasthenia gravis (search).
NMD Pharma (search) presented compelling preclinical data demonstrating the therapeutic potential of ClC-1 (search) ion channel inhibition for treating MuSK myasthenia gravis (search), highlighting improvements in both skeletal muscle function and respiratory function in animal models.
Novel Therapeutic Approach for Myasthenia Gravis
The Danish biotech company showcased research indicating that skeletal muscle specific ClC-1 (search) ion channel inhibitors can improve disease symptoms and progression in MuSK myasthenia gravis (search). According to the presented data, the ClC-1 ion channel regulates the muscle's ability to activate and represents a viable complementary therapeutic target to immunosuppressants and immunomodulatory agents currently used in myasthenia gravis (search) treatment.
The preclinical findings were presented through multiple sessions, including an oral presentation titled "Skeletal muscle targeted ClC-1 (search) ion channel inhibitor improves skeletal muscle function and respiratory function in a rat model of MuSK-MG" and several poster presentations exploring the mechanism of action and clinical development strategy.
Phase 2b Clinical Trial Advancement
NMD Pharma (search)'s lead candidate NMD670, described as a novel, orally bioavailable skeletal muscle specific ClC-1 (search) inhibitor, is currently being evaluated in a Phase 2b clinical trial in patients with generalized myasthenia gravis (search) following positive results from a Phase 2a proof-of-mechanism study.
The Phase 2b study, known as the SYNAPSE-MG dose-finding study, initiated in June 2024 and represents a significant milestone in the development of this first-in-class therapeutic approach. The trial is designed as a dose range-finding, double-blinded, placebo-controlled study evaluating NMD670 over 21 days in generalized myasthenia gravis (search) patients who are anti-acetylcholine receptor (search) (AChR) or anti-muscle-specific tyrosine kinase (search) (MuSK) antibody positive.
Clinical Trial Design and Endpoints
The study will evaluate changes in the Quantitative Myasthenia Gravis (search) Total Score and the Myasthenia Gravis Activities of Daily Living, among other endpoints. The trial is taking place at clinical sites across both the US and Europe, with generalized myasthenia gravis (search) patients who are AChR or MuSK antibody positive encouraged to participate.
Broader Pipeline Development
Beyond myasthenia gravis (search), NMD Pharma (search) is conducting two separate Phase 2 trials evaluating NMD670 in patients living with spinal muscular atrophy (search) and Charcot-Marie-Tooth disease (search), demonstrating the potential broad applicability of ClC-1 (search) ion channel inhibition across multiple neuromuscular disorders.
Company Background and Platform
NMD Pharma (search) A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1 (search)) for the treatment of rare neuromuscular disorders and age-related neuromuscular diseases with high levels of unmet patient need. The company was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity.
The company has built a world-leading muscle electrophysiology platform leveraging in-depth knowledge of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools, as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma (search) has raised approximately €155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.